EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C17H15N9 |
| Net Charge | 0 |
| Average Mass | 345.370 |
| Monoisotopic Mass | 345.14504 |
| SMILES | C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21 |
| InChI | InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1 |
| InChIKey | XYDNMOZJKOGZLS-NSHDSACASA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Biological Role: | c-Met tyrosine kinase inhibitor An EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor that interferes with the action of c-Met tyrosine kinase. |
| Application: | antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| savolitinib (CHEBI:231369) has role antineoplastic agent (CHEBI:35610) |
| savolitinib (CHEBI:231369) has role c-Met tyrosine kinase inhibitor (CHEBI:90199) |
| savolitinib (CHEBI:231369) is a imidazopyridine (CHEBI:46908) |
| savolitinib (CHEBI:231369) is a pyrazoles (CHEBI:26410) |
| savolitinib (CHEBI:231369) is a triazolopyrazine (CHEBI:48277) |
| IUPAC Name |
|---|
| 1-[(1S)-1-(imidazo[1,2-a]pyridin-6-yl)ethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine |
| INNs | Source |
|---|---|
| savolitinib | WHO MedNet |
| savolitinib | WHO MedNet |
| savolitinibum | WHO MedNet |
| savolitinib | WHO MedNet |
| Synonyms | Source |
|---|---|
| volitinib | DrugBank |
| AZD6094 | DrugBank |
| AZD-6094 | SUBMITTER |
| AZD 6094 | ChEBI |
| HMPL-504 | DrugBank |
| 1-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-1,2,3-triazolo[4,5-b]pyrazine | ChEBI |
| Brand Name | Source |
|---|---|
| Orpathys | ChEBI |
| Manual Xrefs | Databases |
|---|---|
| DB12048 | DrugBank |
| D11139 | KEGG DRUG |
| Savolitinib | Wikipedia |
| V0L | PDBeChem |
| Registry Numbers | Sources |
|---|---|
| CAS:1313725-88-0 | KEGG DRUG |
| Citations |
|---|